238 related articles for article (PubMed ID: 26926468)
1. Polypharmacology of Approved Anticancer Drugs.
Amelio I; Lisitsa A; Knight RA; Melino G; Antonov AV
Curr Drug Targets; 2017; 18(5):534-543. PubMed ID: 26926468
[TBL] [Abstract][Full Text] [Related]
2. Polypharmacology: challenges and opportunities in drug discovery.
Anighoro A; Bajorath J; Rastelli G
J Med Chem; 2014 Oct; 57(19):7874-87. PubMed ID: 24946140
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic polypharmacology: from combination therapy to multitargeted drugs.
de Lera AR; Ganesan A
Clin Epigenetics; 2016; 8():105. PubMed ID: 27752293
[TBL] [Abstract][Full Text] [Related]
4. Polypharmacology in Precision Oncology: Current Applications and Future Prospects.
Antolin AA; Workman P; Mestres J; Al-Lazikani B
Curr Pharm Des; 2016; 22(46):6935-6945. PubMed ID: 27669965
[TBL] [Abstract][Full Text] [Related]
5. The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective.
Li YH; Wang PP; Li XX; Yu CY; Yang H; Zhou J; Xue WW; Tan J; Zhu F
PLoS One; 2016; 11(11):e0165737. PubMed ID: 27828998
[TBL] [Abstract][Full Text] [Related]
6. Network pharmacology: the next paradigm in drug discovery.
Hopkins AL
Nat Chem Biol; 2008 Nov; 4(11):682-90. PubMed ID: 18936753
[TBL] [Abstract][Full Text] [Related]
7. Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach.
Ranganna K; Selvam C; Shivachar A; Yousefipour Z
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33147762
[TBL] [Abstract][Full Text] [Related]
8. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
[TBL] [Abstract][Full Text] [Related]
9. Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets.
Skok Ž; Zidar N; Kikelj D; Ilaš J
J Med Chem; 2020 Feb; 63(3):884-904. PubMed ID: 31592646
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic polypharmacology: A new frontier for epi-drug discovery.
Tomaselli D; Lucidi A; Rotili D; Mai A
Med Res Rev; 2020 Jan; 40(1):190-244. PubMed ID: 31218726
[TBL] [Abstract][Full Text] [Related]
11. Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): An update of recent medicinal chemistry efforts.
Ma X; Lv X; Zhang J
Eur J Med Chem; 2018 Jan; 143():449-463. PubMed ID: 29202407
[TBL] [Abstract][Full Text] [Related]
12. In Silico Oncology Drug Repositioning and Polypharmacology.
Cheng F
Methods Mol Biol; 2019; 1878():243-261. PubMed ID: 30378081
[TBL] [Abstract][Full Text] [Related]
13. Multitarget Drug Discovery and Polypharmacology.
Bolognesi ML; Cavalli A
ChemMedChem; 2016 Jun; 11(12):1190-2. PubMed ID: 27061625
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer.
Stazi G; Fioravanti R; Mai A; Mattevi A; Valente S
Curr Opin Chem Biol; 2019 Jun; 50():89-100. PubMed ID: 30986654
[TBL] [Abstract][Full Text] [Related]
15. Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents.
Kathiravan MK; Kale AN; Nilewar S
Mini Rev Med Chem; 2016; 16(15):1219-1229. PubMed ID: 27549098
[TBL] [Abstract][Full Text] [Related]
16. Turning liabilities into opportunities: Off-target based drug repurposing in cancer.
Palve V; Liao Y; Remsing Rix LL; Rix U
Semin Cancer Biol; 2021 Jan; 68():209-229. PubMed ID: 32044472
[TBL] [Abstract][Full Text] [Related]
17. Multi-Targeting Anticancer Agents: Rational Approaches, Synthetic Routes and Structure Activity Relationship.
Singh H; Kinarivala N; Sharma S
Anticancer Agents Med Chem; 2019; 19(7):842-874. PubMed ID: 30657048
[TBL] [Abstract][Full Text] [Related]
18. Exploration of the mechanism of traditional Chinese medicine by AI approach using unsupervised machine learning for cellular functional similarity of compounds in heterogeneous networks, XiaoErFuPi granules as an example.
Guo F; Tang X; Zhang W; Wei J; Tang S; Wu H; Yang H
Pharmacol Res; 2020 Oct; 160():105077. PubMed ID: 32687952
[TBL] [Abstract][Full Text] [Related]
19. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
Noureen N; Rashid H; Kalsoom S
Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
[TBL] [Abstract][Full Text] [Related]
20. Drugs Polypharmacology by In Silico Methods: New Opportunities in Drug Discovery.
Lauria A; Bonsignore R; Bartolotta R; Perricone U; Martorana A; Gentile C
Curr Pharm Des; 2016; 22(21):3073-81. PubMed ID: 26907944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
